Published by ChinaMNC · Yun

Yunnan's 15th Five-Year Plan for Traditional Chinese Medicine Materials: What Foreign Founders Need to Know

Yunnan province has published a plan to reshape its traditional Chinese medicine materials industry by 2030, cutting planting area while raising output value. Here is what foreign founders should understand about the priorities, targets and business openings it sets out.

Yunnan Reshapes Its Herbal Medicine Sector

Yunnan province has issued a development plan for its traditional Chinese medicine materials industry covering the 15th Five-Year Plan period. For foreign founders considering a China company in agribusiness, health products or pharmaceuticals, the plan signals where provincial support is heading and what kinds of activity it is designed to encourage.

The headline logic is unusual: by 2030, the province expects the area planted with medicinal materials to fall by 1.608 million mu, while the target for combined output value rises by 50 billion yuan. In short, Yunnan is trading planted area for quality, processing depth, branding and economic return.

Which Varieties Are Prioritised

The plan builds on the 156 varieties listed in the 2024 edition of Yunnan's catalogue of authentic medicinal materials. It groups future work into three tiers.

• Authentic advantage varieties: the “Top Ten Yunnan Medicines,” led by sanqi (Panax notoginseng). The full list is sanqi, Yunnan Paris polyphylla, fleabane, dendrobium candidum, amomum fruit, gastrodia, Yunnan poria, Yunnan angelica, Yunnan costus and Yunnan gentian.
• Health-oriented specialty varieties: the “Top Ten Health Resources” — Yunnan polygonatum, safflower, bletilla, purple-skin dendrobium, emblic leafflower (Yunnan olive), coix seed, myrobalan, tsaoko, ginger and star anise.
• Potential varieties: the “Six Southern Medicines” — amomum fruit, dragon's blood, cibotium, agarwood, kidney tea and Dai Bai Jie.

For founders, this grouping is a practical map of where provincial attention, standards and processing capacity are likely to concentrate.

Standardised Cultivation and GAP Bases

Yunnan aims to build 200 good agricultural practice (GAP) bases for medicinal materials. The priority is full GAP coverage for Wenshan sanqi, followed in an orderly way by GAP bases for under-forest varieties such as poria, amomum fruit, tsaoko and phellodendron. The province also intends to develop a group of national-level high-standard raw material production bases.

Foreign-invested enterprises looking at upstream supply should note that GAP status is being treated as the benchmark for cultivation. Aligning sourcing contracts with GAP-compliant bases may become a commercial advantage.

Under-Forest Cultivation

Focusing on authentic materials such as sanqi, gastrodia, poria, amomum fruit, polygonatum and phellodendron, the plan promotes under-forest cultivation and rearing. Ecological and under-forest planting bases are to expand to more than six million mu.

This points to opportunities in nursery supply, ecological management, traceability and cooperative models with local growers.

Processing Closer to the Source

The plan supports establishing processing lines in authentic production areas and at high-standard raw material bases. It links GAP-base materials with fresh cutting and pushes products up from primary raw materials to semi-industrialised input materials.

It also encourages enterprises to build modern deep-processing lines, develop higher-value-added products and create a series of Yunnan medicine health products. Research and industrialisation of daily chemical and beauty products and functional wellness products are explicitly included.

For foreign founders, this is the clearest opening: the province wants capital and capability in downstream processing and branded consumer health goods, not simply more raw planting.

Market Stability and Risk Warning

For bulk varieties and scarce varieties vulnerable to market swings — sanqi, angelica and Paris polyphylla are named — the plan calls for market-based adjustment to smooth price volatility. It also calls for an information monitoring and early-warning system to flag risks such as盲目 expansion of planting and prices falling so low that growers are harmed.

Companies building supply chains should expect greater attention to planting data and may find early-warning information useful for procurement planning.

Food-Medicine Homology and Cross-Border Registration

Yunnan plans to set standards for food-medicine homology raw materials and production and processing specifications. It aims to complete cross-border registration and launch of five to ten new products, and to plan a “Yunnan Medicine Food-Medicine Homology Culture Festival.”

Cross-border registration is directly relevant to founders with regional ambitions: it suggests a pathway for products positioned at the boundary of food and medicine, subject to the standards being developed.

The “Yunnan Medicine Brain”

The plan includes an artificial intelligence innovation application project called the “Yunnan Medicine Brain.” It envisages an intelligent application system covering the full life cycle of medicinal materials, with multi-level and multi-scenario solutions in key areas.

This may create demand for technology partners in data, monitoring and smart agriculture, though the plan does not specify procurement or participation mechanisms.

Practical Takeaways for Founders

• Upstream: GAP bases and under-forest cultivation are the stated direction; expect standards and traceability to matter in supply agreements.
• Midstream: Origin processing and fresh cutting are being linked to GAP materials, favouring integrated supply models.
• Downstream: Deep processing, daily chemical and beauty products and functional wellness goods are encouraged.
• Market: Monitoring and early warning for bulk varieties may affect price planning.
• Cross-border: Five to ten new food-medicine homology products are targeted for cross-border registration.

Foreign founders should treat the plan as a statement of provincial direction rather than an operating licence. Specific incentives, land arrangements, registration requirements and investment rules are not set out in the source and would need to be confirmed with the relevant authorities and professional advisers.

This summary is based on information published by the relevant Chinese government website and is general information, not legal or tax advice.